ClinicalTrials.gg
RecruitingNCT06354764eCREAM-UC1Updated Oct 9, 2026

Propensity to Hospitalize Patients From the ED in European Centers.

An observational study in Emergency Medicine, sponsored by Mario Negri Institute for Pharmacological Research. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Mario Negri Institute for Pharmacological Research · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
162,000
Ages
18 Years and older
Sex
All
01

Study summary

The peer-to-peer comparison means center-to-center comparison, which requires adjusting for possible differences among centers to be fair and convincing. The first step to reach this goal is to develop a predictive model that accurately estimates each patient's probability of being admitted, starting from clinical conditions and boundary variables. Such a model would make it possible to calculate, for each ED, the expected hospitalization rate; that is, the hospitalization rate that would have been observed if the ED had behaved like the average of the EDs that provided the data to build the model itself. Comparing the observed hospitalization rate in the single ED with the expected rate derived from the model provides a rigorous method of comparing the department with the average performance, taking into account the characteristics of the patients treated and the conditions under which the ED operated. In other words, the predictive model represents the benchmark against which each ED is evaluated.

02

Conditions studied

  • Emergency Medicine
03

In context

Lead sponsor

Mario Negri Institute for Pharmacological Research is the lead sponsor of 161 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

All adult patients who arrived at participating emergency departments between January 1, 2021 and December 31, 2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult
  • Arrived at emergency department between 1 January 2021 and 31 December 2023

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
162,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults who attended the emergency department

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Create two separate databases

    To create two separate databases (one for each of the two subgroups considered) on all patients who presenteding to the participating EDs over a defined period, containing the information considered important to study both the propensity to hospitalize these patients and their 30-day mortality

    Time frame: September 2024 - September 2025

  2. Multivariable models

    To develop two multivariable models that predict the probability that patients presenting to the ED with dyspnea (first model) or after a TLoC (second model) will be admitted to the hospital

    Time frame: September 2025 - September 2026

  3. Adjusted comparison

    To provide the participating EDs with an adjusted comparison of the hospitalization rates for the patients with selected symptoms, to improve the quality of care.

    Time frame: September 2025 - September 2026

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — eCREAM-UCI1 will join the MIP (Medical Informatics Platform), developed in the Human Brain Project (HBP), to federate clinical data. The MIP is an open-source, GDPR-compliant, privacy-aware platform, enabling remote and federated analyses from datasets physically distributed in various hospitals, research centers, and biobanks, without moving the data outside their original storage site to a central repository. Patient identification data will be deleted from the databases before these are uploaded to the MIP platform, and no pseudo-identifier will be available. See https://mip.ebrains.eu/ for more details on the MIP.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 9, 2024
StartActual
Sep 22, 2025
Primary completionEst.
Jan 2027was Jun 2026
CompletionEst.
Feb 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jan 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Jun 2026→Jan 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06354764
Collaborators
Astir s.r.l., Centre Hospitalier Universitaire Vaudois, Orobix Life S.r.l., Fondazione Bruno Kessler
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Sep 22, 2025
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Chiara Pandolfini
Contact
chiara.pandolfini@marionegri.it
0039 02 39014 253
Giulia Ghilardi
Contact
giulia_irene.ghilardi@marionegri.it
0039 035 4535 389
Guido Bertolini, MD
principal investigator · Istituto Di Ricerche Farmacologiche Mario Negri

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion